Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter SARS-CoV-2 Spike S1 Antikörper (RBD)

Reaktivität: SARS Coronavirus-2 (SARS-CoV-2) ELISA, Neut, GICA Wirt: Human Monoclonal A1 unconjugated single-domain Antibody (sdAb) Recombinant Antibody
Produktnummer ABIN6953152
  • Target Alle SARS-CoV-2 Spike S1 Antikörper anzeigen
    SARS-CoV-2 Spike S1
    Antikörpertyp
    Recombinant Antibody
    Fragment
    single-domain Antibody (sdAb)
    Bindungsspezifität
    • 13
    • 3
    • 2
    • 2
    • 1
    RBD
    Reaktivität
    • 44
    • 7
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    SARS Coronavirus-2 (SARS-CoV-2)
    Wirt
    • 18
    • 10
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    Human
    Klonalität
    • 31
    • 9
    • 5
    Monoklonal
    Konjugat
    • 39
    • 3
    • 1
    • 1
    • 1
    Dieser SARS-CoV-2 Spike S1 Antikörper ist unkonjugiert
    Applikation
    • 44
    • 9
    • 9
    • 7
    • 5
    • 5
    • 5
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Neutralization (Neut), Colloidal Gold Immunochromatography Assay (GICA)
    Produktmerkmale
    This SARS-CoV-2 Spike RBD Nanobody is a recombinant monoclonal antibody generated through the expression of a DNA sequence inserting a human IgG1 Fc domain at the C-terminus, in human embryonic kidney 293 cells (HEK293). The DNA sequence encodes the SARS-CoV-2 spike receptor-binding domain (RBD). The antibody is purified by protein G in vitro. It has been validated with high reactivity towards SARS-CoV-2-S1-RBD by a functional ELISA and good sensitivity for human SARS-CoV-2 spike glycoprotein (S protein) via the Colloidal Gold Immunochromatography Assay (GICA). In neutralization assay, the binding signal of SARS-CoV-2 Spike RBD Nanobody was inhibited by ACE2 protein-HRP conjugated inhibitor, with a 0.1074 μg/mL IC50. Specifically binding and recognizing the RBD of the SARS-CoV-2 spike glycoprotein (S protein), so the SARS-CoV-2 Spike RBD Nanobody can react with samples infected with human coronavirus SARS-CoV-2. But it does not respond to MERS or SARS-CoV spike protein. Akin to other nanobodies, this recombinant nanobody is small and stable, which allows for its reaching to hidden epitopes such as crevices of target proteins.
    VHH fusion with human IgG1 Fc
    Aufreinigung
    affinity-chromatography
    Immunogen
    Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa)
    Klon
    A1
    Isotyp
    IgG1
    Featured
    Zu unserem meistverkauften SARS-CoV-2 Spike S1 Primärantikörper
    Top Product
    Discover our top product SARS-CoV-2 Spike S1 Primärantikörper
  • Applikationshinweise
    ELISA 1:10000-1:100000
    GICA 1:10000-1:40000
    Neutralising 1:100-1:10000
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    50 % Glycerol, 0.01M PBS, pH 7.4, 0.03 % Proclin 300
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C,-80 °C
    Informationen zur Lagerung
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze
  • Target
    SARS-CoV-2 Spike S1
    Abstract
    SARS-CoV-2 Spike S1 Produkte
    Synonyme
    E2 antikoerper, Surface Glycoprotein antikoerper, S antikoerper
    Substanzklasse
    Viral Protein
    Hintergrund
    Spike glycoprotein comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and fusion of the viral and cellular membranes (S2 subunit). For many coronavirus (CoVs), S is cleaved at the boundary between the S1 and S2 subunits, which remain non-covalently bound in the prefusion conformation. The distal S1 subunit comprises the receptor-binding domain(s) and contributes to stabilization of the prefusion state of the membrane-anchored S2 subunit that contains the fusion machinery. S is further cleaved by host proteases at the so-called S2' site located immediately upstream of the fusion peptide in all CoVs. This cleavage has been proposed to activate the protein for membrane fusion via extensive irreversible conformational changes. However, different CoVs use distinct domains within the S1 subunit to recognize a variety of attachment and entry receptors, depending on the viral species. Endemic human coronaviruses OC43 and HKU1 attach via their S domain A to 5-N-acetyl-9-O-acetyl-sialosides found on glycoproteins and glycolipids at the host cell surface to enable entry into susceptible cells. MERS-CoV S uses domain A to recognize non-acetylated sialoside attachment receptors, which likely promote subsequent binding of domain B to the entry receptor, dipeptidyl-peptidase 4. SARS-CoV and several SARS-related coronaviruses (SARSr-CoV) interact directly with angiotensin-converting enzyme 2 (ACE2) via SB to enter target cells.
    Gen-ID
    43740568
    UniProt
    P0DTC2
Sie sind hier:
Kundenservice